CalciMedica Inc. (NASDAQ:CALC) Short Interest Up 497.8% in June

CalciMedica Inc. (NASDAQ:CALC) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,651,945 shares, an increase of 497.8% from the June 15th total of 276,326 shares. Based on an average trading volume of 6,188,729 shares, the short-interest ratio is presently 0.3 days. Approximately 17.9% of the shares of the company are short sold.

CalciMedica Trading Down 2.1%

CALC traded down $0.02 on Friday, reaching $0.93. The company had a trading volume of 178,067 shares, compared to its average volume of 3,405,775. The company has a fifty day moving average of $0.79 and a 200-day moving average of $1.63. The company has a market capitalization of $14.69 million, a P/E ratio of -0.71 and a beta of 0.89. CalciMedica has a one year low of $0.46 and a one year high of $7.20.

Insider Activity at CalciMedica

In related news, Director Fred A. Middleton bought 248,972 shares of the stock in a transaction dated Thursday, June 25th. The stock was bought at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This trade represents a 30.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 41.55% of the company’s stock.

Institutional Trading of CalciMedica

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in shares of CalciMedica in the fourth quarter valued at approximately $127,000. Cetera Investment Advisers raised its holdings in CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares in the last quarter. PVG Asset Management Corp acquired a new stake in CalciMedica in the fourth quarter worth approximately $302,000. Boothbay Fund Management LLC acquired a new stake in CalciMedica in the fourth quarter worth approximately $506,000. Finally, Renaissance Technologies LLC boosted its stake in CalciMedica by 26.1% during the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares in the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CalciMedica in a research note on Tuesday, July 7th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.